KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
10.69
-0.22 (-2.02%)
Nov 3, 2025, 10:16 AM EST - Market open
KalVista Pharmaceuticals Revenue
KalVista Pharmaceuticals had revenue of $1.43M in the quarter ending July 31, 2025. This brings the company's revenue in the last twelve months to $1.43M.
Revenue (ttm)
$1.43M
Revenue Growth
n/a
P/S Ratio
386.54
Revenue / Employee
$5,281
Employees
270
Market Cap
540.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | - | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | - | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | - | - | - |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
KALV News
- 4 days ago - KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - Business Wire
- 27 days ago - KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress - Business Wire
- 5 weeks ago - KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes - Business Wire